1American Cancer Society. Cancer Facts & Figures 2004. Atlanta, GA : American Cancer Society,2004, 22-23.
2Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin,2000,50:7-33.
3Jemal A, Murray T, Samuel A, et al. Cancer statistics,2003. CA Cancer J Clin,2003 ,53 :5-26.
4Landis SH, Murray T, Bolden S, et al. Cancer statistics,1999. CA Cancer J Clin, 1999,49:8-31.
5Mountain CF. International staging system for lung cancer. In : Pass H, Mitchell J, Johnson D, Turrisi A, Minna J, eds. Lung cancer, second. Philadelphia : Lippincott Wiliams Wilkin ,2000,591 -601.
6Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ, 1995, 311: 899-909.
7Gandara DR, Crowley J, Livingston RB, et al, Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol, 1993,11 : 873 -878.
8Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol, 2004,22:3852- 3859.
9Ardizzoni A, Boni L, Tiseo M, et al. Cisplatinversus carboplatin-based chemotherapy in first-line treatment of advanced non-small- cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst, 2007, 99 : 847-857.
10Monnet I, Brienza S, Hugret F, et al. Phase Ⅱ study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). Eur J Cancer, 1998, 34 : 1124-1127.
5[2]McKeage MJ.Lobaplatin:a new antitumour platinum drug[J].Expert Opin Investig Drugs,2001,10(1):119-128.
6[4]The Non-Small Cell Lung Cancer Collaborative Group.Chemotherapy in non-small cell lung cancer:a meta-analysis using up dated data on individual patients from 52 randomized clinical trials[J].BMJ,1995,311:899-909.
7[5]Wozniak A,Crowley J,Balcerzak SP,et al.Randomized trial comparing cisplatin with cisp-latin plus vinorelbine in the treatment of advanced non-small cell lung cancer:a Southwest Oncology Group study[J].J Clin Oncol,1998,16:2459-2465.
8[6]Saris CP,Van De VP,Rietbroek RC,et al.In vitro formation of DNA adducts by cisplatin,lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells[J].Carcinogenesis,1996,17(12):2763-2769.
9[7]Fiebig HH,Henb H,Vonpawel I,et al.Phase Ⅱ clinical trial of lobaplatin (D-19466) in pretreated patients with small-cell lung cancer[J].Onkologie,1996,19:328-332.
10[10]Manegold C,Drings P,Gatzemeier U,et al.Lobaplatin (D-19466) in patients with advanced non-small-cell lung cancer:a trial of the association for medical oncology (AIO) phase Ⅱ study group[J].Onkologie,1996,19:248-251.
4Sibanda BL, Chirgadze DY, Blundell TL. Crystal structure of DNA- PKcs reveals a large open-ring cradle comprised of HEAT repeats. Nature,2010,463 : 118-121.
5Cho BC,Kim JH,Soo RA,et al. The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer. Yonsei Med J,2010,51:1-8.
6Yang CT, Hung JY, Lai CL, et al. Gefitinib as first-line therapy for advanced or metastatic non-small cell lung cancer patients in southern Taiwan. Kaohsiung J Med Sci ,2010,26 : 1-7.
7Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung carcinoma:current status and future prospects. Eur Respir J,2010,35:202-215.
8Shao CJ,Fu J, Shi HL, et al. Activities of DNA-PK and Ku86, but not Ku70, may predict sensitivity to cisplatin in human gliomas. J Neurooncol, 2008,89:27-35.
9Komuro Y, Watanabe T, Hosoi Y, et al. The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma. Cancer,2002,95 : 1199-1205.
10Tseng RC, Hsieh FJ, Shih CM,et al. Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end- joining pathway genes: a multiple genotype-phenotype study. Cancer,2009,115:2939-2948.
